The Claim
The inverse agonist CID-2745687 increases colonic epithelial barrier permeability in humanized transgenic mouse colonoids and human cell lines expressing GPR35, but does not increase colonic epithelial barrier permeability in GPR35-knockout models.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
CID-2745687 increases the permeability of the colon lining in cells that express the GPR35 protein, but does not increase permeability in cells that lack the GPR35 protein.
See the scientific wording
The inverse agonist CID-2745687 increases colonic epithelial barrier permeability in humanized transgenic mouse colonoids and human cell lines expressing GPR35, but has no effect in GPR35-knockout models, indicating its action is specific to suppression of constitutive GPR35 activity.
The GPR35 receptor is always slightly active in gut lining cells, sending a continuous signal through Gα12 and Gα13 proteins to keep the tight seals between cells strong. When a drug blocks this constant signal, the seals loosen and the barrier becomes leaky. If the receptor is missing, the drug does nothing because there is no signal to block.
What the research says
1 studyThis drug blocks a natural signal from a receptor called GPR35 that helps keep the gut lining tight. When the receptor is present, the drug makes the lining leakier; when the receptor is gone, the drug does nothing — proving it only works by turning off that specific receptor.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.